Immunostimulatory Oligonucleotides
AssigneePfizer Inc.
InventorsHEATHER DAVIS, RISINI WEERATNA
Life of this patent
Estimating the term…
Abstract
The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antigen, and comprises a pharmaceutically acceptable carrier. The immunostimulatory oligonucleotides of the invention, in some embodiments, include one or more modified linkage(s).
Claims27
An immunostimulatory oligonucleotide comprising the nucleotide sequence
- 5′ TCGTCGTTTTTCGGTGCTTTT 3′ (SEQ ID NO:1).
A vaccine comprising
- an antigen and an immunostimulatory oligonucleotide comprising the nucleotide sequence SEQ ID NO:1, further comprising a pharmaceutically acceptable carrier.
-16. (canceled)
-22. (canceled)
-27. (canceled)
-49. (canceled)
-52. (canceled)
A method of inducing an antigen-specific immune response in a subject in need thereof comprising
- administering to a subject an antigen and an immunostimulatory oligonucleotide comprising nucleotide sequence SEQ ID NO:1 in an effective amount to induce an antigen-specific immune response in said subject.
-104. (canceled)
Dependencies are inferred from the claim text.